Browsing by Author "Bilici, Ahmet"
Now showing items 1-3 of 3
-
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gurbuz, Mustafa; Kutlu, Yasin; Akkus, Erman; Koksoy, Elif Berna; Kose, Naziyet; Oven, Bala Basak; Uluc, Basak Oyan; Demiray, Atike Gokcen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Uskent, Necdet; Akbas, Sinem; Selcukbiricik, Fatih; Inal, Ali; Bilici, Ahmet; Kilickap, Saadettin (Springer, 2022)Purpose Atezolizumab has been shown to be efective and safe in randomized trial in the frst-line treatment of extensivestage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this ... -
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: a real-life data of Turkish oncology group
Gürbüz, Mustafa; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Fulden Yumuk, Perran; Gürsoy, Pinar; Uysal, Mükremin; Şenol Coşkun, Hasan; Kilickap, Saadettin (Lippincott Williams and Wilkins, 2022)Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib ... -
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Tatli , Ali Murat; Erdem, Dilek; Goker, Erdem; Celik, Emir; Demirci, Nebi Serkan; Sakin, Abdullah; Atci , Muhammed Mustafa; Bayram, Ertuğrul; Akın Telli, Tuğba; Bilgin, Burak; Bilici, Ahmet; Akangunduz , Baran; Balli, Sevinç; Demirkazik, Ahmet; Selçukbiricik, Fatih; Menekse, Serkan; Cavdar, Eyyüp; Ozturk, Akın; Türkmen Bekmez, Esma; Turhal, Serdal; Kilickap, Sadettin; Yildirim, Hasan Çağrı; Oyan, Başak; Aksoy, Asude; Paksoy Turkoz, Fatma; Kut, Engin; Katgi, Nuran; Sakalar, Teoman; Akyol, Murat; Ellez, Halil İbrahim; Topcu, Atakan; Erdoğan, Atike Pınar; Pilanci, Kezban Nur; Hedem, Engin; Arak, Hacı; Akdeniz, Nadiye; Alan, Özkan; Yapar, Burcu; Nart, Deniz; Yumuk, Perran Fulden (Springer, 2022)Objectives To compare the survival of frst- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ...
